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The cytokine Tumour Necrosis Factor Superfamily member 14, TNFSF14 (or LIGHT), is a 43 
controversial player in numerous diseases. We investigated the role of mouse TNFSF14 in 44 
diet-induced obesity in vivo. Specifically, we studied the effects of a global deletion of the 45 
TNFSF14 gene on the development of obesity, glucose intolerance, insulin resistance, 46 
steatosis, tissue inflammation and mitochondrial respiration in the liver. Secondly, we 47 
examined the role of TNFSF14 expression in hematopoietic cells on obesity and insulin 48 
sensitivity.  49 
Male TNFSF14 knockout and wildtype mice were fed chow or high fat diet (HFD) for 12 50 
weeks. In other experiments, wildtype mice were reconstituted with bone marrow cells 51 
from TNFSF14 KO mice and were fed chow or HFD for 12 weeks. All mice were metabolically 52 
phenotyped.  53 
We show that HFD fed wildtype mice had elevated circulating levels of TNFSF14 in their 54 
serum. Liver and white adipose tissue are potential sources of this elevated TNFSF14. 55 
Excitingly, TNFSF14 deficient mice displayed markedly increased obesity, glucose 56 
intolerance, insulin resistance, hepatosteatosis and mitochondrial defects compared to 57 
wildtype mice on a HFD. Hepatic cytokine profiling pointed to a potential novel role of 58 
decreased IL-6 in the metabolic disturbances in obesogenic TNFSF14 KO mice. Finally, bone 59 
marrow cells from TNFSF14 deficient mice were able to contribute to promoting diet-60 
induced obesity and insulin resistance.  61 
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Our novel data suggest that TNFSF14 ablation exacerbates parameters of the metabolic 62 
syndrome under high fat feeding conditions and provides further evidence to support the 63 




















Global prevalence of obesity in adults has been significantly rising since the 1980s (Ng, et al. 82 
2014) resulting in adverse metabolic conditions such as glucose intolerance, insulin 83 
resistance, inflammation, dyslipidemia and ultimately type 2 diabetes (T2D). Alarmingly, the 84 
cluster of pathologies characteristic of obesity-dependent type 2 diabetes, collectively 85 
referred to as ‘diabesity’, has started to emerge in children (Chen, et al. 2012; Farag and 86 
Gaballa 2011; Ng et al. 2014). This phenomenon warrants the urgent need to develop 87 
strategies to treat diabesity. Current diabesity treatment options initially focus on lifestyle 88 
modifications such as healthy diet, controlled caloric intake and increased physical exercise. 89 
Bariatric surgery is sometimes recommended (Colquitt, et al. 2014), although drug therapy 90 
is a viable intervention for those in whom lifestyle modification has failed (Li, et al. 2005; 91 
Sweeting, et al. 2015). Disappointingly, commonly used anti-obesity drugs have not resulted 92 
in consistent and effective weight loss (Li et al. 2005; Padwal and Majumdar 2007; Sweeting 93 
et al. 2015) and consequently there is great interest in developing new therapies to reduce 94 
obesity. 95 
 96 
A number of secreted factors have been implicated in the etiology of obesity and insulin 97 
resistance in rodents and humans (Hotamisligil, et al. 1995; Hotamisligil, et al. 1993; Krogh-98 
Madsen, et al. 2006; Steinberg, et al. 2006). One soluble factor of interest in alleviating the 99 
characteristics of diabesity is the Tumour Necrosis Factor Superfamily member TNFSF14 100 
(also known as LIGHT; Lymphotoxin-like, exhibits Inducible expression, competes with 101 
Herpes Simplex Virus Glycoprotein D for Herpesvirus Entry Mediator [HVEM] receptor 102 
expressed by T lymphocytes). A number of studies have elegantly described a beneficial role 103 
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for TNFSF14 in numerous diseases. TNFSF14 has been shown to assist in wound healing 104 
(Dhall, et al. 2016), stem cell therapy (Heo, et al. 2016) and in skeletal muscle regeneration 105 
(Waldemer-Streyer and Chen 2015). It is also reported that TNFSF14 serves a protective role 106 
in multiple sclerosis (Malmestrom, et al. 2013), experimental autoimmune 107 
encephalomyelitis (Mana, et al. 2013) and intestinal inflammation (Krause, et al. 2014).  108 
Finally, a recent study presented that TNFSF14 is a potential immunotherapeutic agent to 109 
treat colon cancer (Qiao, et al. 2017).   110 
 111 
Currently controversy surrounds the role of TNFSF14 in the development of the metabolic 112 
syndrome. Serum TNFSF14 levels are reportedly increased in morbidly obese humans 113 
(Bassols, et al. 2010a) and the expression of TNFSF14 is reduced in patients who do not have 114 
T2D compared with type 2 diabetic patients (Dandona, et al. 2014). However it remains to 115 
be elucidated whether TNFSF14 is functionally upregulated in the progression of the 116 
metabolic syndrome in a pro- or anti-obesogenic manner. Furthermore, the exact source of 117 
elevated TNFSF14 during the metabolic syndrome is unknown, although TNFSF14 is strongly 118 
expressed in multiple immune cells including resting and activated T cells, B cells, 119 
monocytes and macrophages (Kwon, et al. 1997). Adding complexity to this signalling 120 
cascade, TNFSF14, which may be expressed on the cell surface, secreted or cleaved by 121 
metalloproteinases, is considered a promiscuous ligand as it signals via the lymphotoxin- 122 
receptor (LTR) and herpesvirus entry mediator (HVEM). The HVEM receptor is highly 123 
expressed in visceral adipose tissue (Bassols, et al. 2010b) and both LTR and HVEM are 124 
expressed in pancreatic  cells (Han and Wu 2009). Interestingly, treatment of human 125 
primary adipocytes with TNFSF14 resulted in a potent inhibition of adipocyte differentiation, 126 
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which suggests that TNFSF14 may be metabolically beneficial (Tiller, et al. 2011) although 127 
this remains to be comprehensively investigated.  128 
 129 
We are the first research team to utilise a TNFSF14 knockout mouse to investigate the 130 
functional role of TNFSF14 in obesity, insulin signalling, inflammation, hepatosteatosis, 131 
cytokine signalling pathways and mitochondrial respiration. Secondly, our study determines 132 
the cellular sources of TNFSF14 that may attenuate diet-induced obesity. The outcomes of 133 
this study provide compelling evidence that TNFSF14 is necessary to limit the pathogenesis 134 
of the metabolic syndrome and our data supports the development of agonists of TNFSF14 135 













MATERIALS AND METHODS 147 
Diet-induced obesity mouse model 148 
Eight week old C57BL6/J mice were administered either a normal chow (chow) or high fat 149 
diet (HFD) (Speciality Feeds, Glen Forrest, WA Australia) for 12 weeks.  Mice had free access 150 
to food and water. Body weights were measured weekly for all mice. Intraperitoneal glucose 151 
tolerance tests (GTT; 1 g/kg) and insulin tolerance tests (ITT; 0.5 U/kg) were performed in 152 
mice fasted for 6 hours on week 11 and 12 of the diet regiment respectively. After 12 weeks 153 
on their respective diets, mice were anaesthetised with methoxyflurane, underwent cardiac 154 
puncture to obtain blood and were euthanised by cervical dislocation. Tissues were 155 
collected and either fixed in paraformaldehyde and subsequently embedded in paraffin for 156 
immunohistochemistry experiments, frozen in OCT embedding medium for oil red staining, 157 
or snap-frozen and stored at -80C for mRNA and protein expression studies. All animal 158 
experimentation was approved by the Royal Perth Hospital Animal Ethics Committee and 159 
were conducted in accordance with the National Health and Medical Research Council of 160 
Australia Guidelines on Animal Experimentation. 161 
 162 
Tumour Necrosis Factor Superfamily Member 14 knockout mouse model 163 
Tumour Necrosis Factor Superfamily Member 14 knockout (TNFSF14 KO) mice display no 164 
major developmental defects (Scheu, et al. 2002). The TNFSF14 mice were backcrossed 8 165 
generations to C57BL6/J mice to reduce genetic heterogeneity. Eight week old male 166 
wildtype (WT) and TNFSF14 KO mice on a C57BL6/J background were administered either a 167 
normal chow or HFD (Speciality Feeds, Glen Forrest, WA, Australia) for 12 weeks. Mice were 168 
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weighed weekly and GTTs or ITTs were conducted and serum/tissue collection occurred as 169 
described previously.  170 
 171 
Bone marrow mouse model 172 
Using methodology previously described (Bollrath, et al. 2009; Ernst, et al. 2008) six week-173 
old male C57BL6/J mice were lethally irradiated with two 5.5-Gy doses of gamma-irradiation 174 
from a 137Cs source (Gammacell 3000 Elan; MDS Nordion, Kanata, ON, Canada) separated by 175 
a 4-h interval. As the TNFSF14 KO mice are on a C57BL/6J background and express the 176 
alloantigen CD45.2 on their hematopoietic cells, we used congenic Pep3b B6 SJL/.Ly5.1 mice 177 
(Animal Resources Centre, WA, Australia) as the WT counterparts because they express 178 
CD45.1 on their hematopoietic cells. This critically allowed distinction to be made between 179 
donor and recipient lymphocytes by flow cytometry. After the second dose of irradiation, 180 
WT mice were reconstituted with 2 million whole bone marrow cells from TNFSF14 KO mice 181 
and given drinking water containing antibiotics (1.1g/L neomycin sulfate and 1000U/L 182 
polymyxin B sulfate) for the first 2 weeks post-irradiation. Six weeks post-transplant, mice 183 
were administered either normal chow or HFD for 12 weeks. Mice were subjected to all of 184 
the aforementioned metabolic studies.  185 
 186 
Cell culture experiments 187 
L6 myoblast cells were purchased from the American Type Culture Collection (Manassas, 188 
Virginia, USA). Cells were cultured at 37°C, 5% CO2 in a humidified chamber. L6 myoblasts 189 
were seeded in 6 well culture plates and grown in low glucose Dulbecco's Modified Eagle 190 
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Medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin (Thermo 191 
Fisher, Melbourne, Victoria, Australia). Differentiation of the myoblasts was induced by 192 
transferring cells to medium containing 2% fetal calf serum when the myoblasts were ~90% 193 
confluent. Experimental treatments commenced after 7 days of differentiation when nearly 194 
all myoblasts had fused to form myotubes. Upon the day of experimentation, cells were 195 
serum starved for 4hrs. Media was changed to low glucose DMEM containing 4% fatty acid 196 
free BSA with palmitate (0.75 mM) to induce insulin resistance, or without palmitate, and 197 
cells were incubated for 24 hours. Cells were also treated with or without mouse TNFSF14 198 
(100 ng/mL; Peprotech, Rocky Hill, USA) for the same 24hr incubation. Cells were then 199 
treated with or without insulin (250 ng/mL) for 30min before cells were lysed. 200 
 201 
Confluent mouse pancreatic  cells, MIN6, were grown in high glucose (4.5 g/L) DMEM. Cells 202 
were treated with mouse TNFSF14 (200 ng/mL; Peprotech) for 48hrs. Media was then 203 
changed to low glucose (1 g/L) DMEM. After 45min, the low glucose DMEM was changed to 204 
high glucose (4.5 g/L) DMEM for 45min. Cell-free culture supernatant was collected and 205 
subjected to a mouse insulin ELISA (EZRMI-13K; Millipore, Australia).   206 
 207 
Gene expression assays 208 
RNA from murine tissue was extracted using Trizol reagent (Invitrogen, Thermo Fisher, 209 
Melbourne, Victoria, Australia) and cDNA synthesis was performed using the High Capacity 210 
RNA-to-cDNA kit (Applied Biosystems, Thermo Fisher, Melbourne, Victoria, Australia). Real-211 
time PCR was performed to determine the mRNA abundance utilising a Rotor-gene real-212 
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time PCR machine (Qiagen, Hilden, Germany) using pre-developed TaqMan probe (FAM 213 
labelled) and primer sets for HPRT (Mm01545399_m1); CXCL-10 (Mm00445234_m1); TNF- 214 
(Mm00443260_g1) and TNFSF14 (Mm00619239_m1) (Applied Biosystems). Quantitation 215 
was conducted as previously described (Chan, et al. 2004). 216 
 217 
Enzyme Linked Immunosorbant Assays 218 
Serum was collected and analysed for circulating TNFSF14 levels as per manufacturer’s 219 
instructions (CSB-EL023991MO; Cusabio Biotech Co. Ltd, China). Serum was also analysed 220 
for circulating insulin using an insulin ELISA (EZRMI-13K; Millipore, Australia).   221 
Liver tissue was collected and homogenised in cytosolic extraction buffer (10mM HEPES, 222 
3mM MgCl2, 14mM KCl, 5% glycerol, 0.2% IPEGAL) containing phosphatase  and protease 223 
inhibitors (Roche Diagnostics, Indianapolis, Indiana, USA). Protein concentration was 224 
quantified using protein assay solution (Bio-Rad, Hercules, California, USA). Protein lysates 225 
were analysed for IL-6, IL-10, IL-1 and IL-18 according to manufacturer’s instructions 226 
(ELISAKit.com, Scoresby, Victoria, Australia).  227 
 228 
Western blotting 229 
Rat L6 myotubes were lysed or murine liver tissue was homogenised using cytosolic 230 
extraction buffer containing phosphatase and protease inhibitors and protein concentration 231 
was quantified using protein assay solution (Bio-Rad, Hercules, California, USA). Protein 232 
lysates were solubilized in Laemmeli sample buffer and boiled for 10 min, resolved by SDS-233 
PAGE on 10% polyacrylamide gels, transferred by semi-dry transfer to PVDF membrane and 234 
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then blocked with 5% milk powder. Membranes were incubated overnight in primary 235 
antibody [phospho-AKT Ser473 (9271; Cell Signalling Technology Inc, Danvers, 236 
Massachusetts, USA); hepatic Lipase H-70 (sc-21007; Santa Cruz Biotechnology Inc, Dallas, 237 
Texas, USA) or mouse anti- actin antibody (ab6276; Abcam, Cambridge, UK)] using 238 
recommended dilutions. Membranes were washed 3 times and the appropriate secondary 239 
antibody was added to the membranes (GE Healthcare Australia, Parramatta, New South 240 
Wales, Australia). Detection of the relevant protein was performed via enhanced 241 
chemiluminescence (GE Healthcare) and visualised using a Multilmage II FC Light Cabinet 242 
(Alpha Innotech Corporation, San Leandro, California, USA). Densitometry was performed 243 
using the AlphaImager software (Alpha Innotech Corp.). 244 
 245 
Haematoxylin and eosin staining  246 
Mouse gonadal adipose tissue was dissected and fixed in 4% paraformaldehyde overnight 247 
before being incubated in 50% ethanol (by volume) and then promptly embedded with 248 
paraffin. Adipose tissue was cut into 5µM sections and stained with haematoxylin (Sigma-249 
Aldrich, Sydney, New South Wales, Australia) and eosin (Sigma-Aldrich). 250 
 251 
Oil red lipid staining 252 
Freshly sectioned snap-frozen livers were fixed using 10% Formalin. Slides were then 253 
washed in 60% isopropanol and stained with Oil Red (O0625; Sigma-Aldrich) for 15 minutes. 254 
Slides were washed in 60% isopropanol and lightly stained with Harris Modified Hematoxylin 255 
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Solution (HHS32-1L; Sigma-Aldrich). Slides were washed in water and mounted using 256 
gelatin/glycerol.  257 
 258 
Immunohistochemistry for hepatic lipase expression 259 
Paraffin embedded liver tissue was sectioned at 5µM onto slides and de-waxed in xylene 260 
and rehydrated in ethanol. Antigen retrieval was performed on the slides by heating in EDTA 261 
buffer (pH 8.5; Sigma-Aldrich). Endogenous peroxidases were blocked with 3% hydrogen 262 
peroxide solution and tissue was then blocked in 5% FCS. Sections were then incubated in 263 
hepatic lipase (H-70) antibody (sc-21007; Santa Cruz), followed by anti-rabbit antibody 264 
conjugated to horse-radish peroxidase (GE Healthcare), followed by treatment with 265 
diaminobenzidine (DAB; DAKO). Tissues were dehydrated in ethanol and xylene and 266 
mounted with DPX (Sigma-Aldrich). 267 
 268 
Hepatic mitochondrial respiration study 269 
Mouse liver mitochondria were isolated using a standard procedure involving 270 
homogenisation and differential centrifugation (Chappell and Hansford 1972). 271 
Mitochondrial respiration was measured using glutamate/malate, succinate/rotenone and 272 
ascorbate/TMPD (N,N,N’,N’-tetramethyl-p-phenylenediamine dihydrochloride) according to 273 
Kuznetsov et al. (Kuznetsov, et al. 2008). Briefly, 80 µg of isolated mitochondria were 274 
resuspended in mitomedium B (0.5 mM EGTA, 3 mM MgCl2, 20mM taurine, 10 mM KH2PO4, 275 
20 mM HEPES, 1 g.l-1 fatty acid-free BSA, 60 mM lactobionate, 110 mM mannitol, 0.3 mM 276 
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DTT, pH 7.1 with KOH) and added to a 2 mL OROBOROS Oxygraph-2K Oxygen Electrode 277 
thermostatically maintained at 37˚C.  278 
 279 
Statistical analysis 280 
All quantitative data are presented as mean + or - SEM. A significance level of p<0.05 was 281 
considered significant. Significance was determined using 2-way ANOVA or Student t-tests. 282 

















Serum TNFSF14 levels are elevated with diet-induced obesity. 298 
 We demonstrate that WT mice fed a high fat diet (HFD) possess elevated levels of 299 
circulating TNFSF14 protein (Figure 1A) as well as increased TNFSF14 mRNA expression in 300 
metabolically relevant tissues including white adipose tissue (Figure 1B) and liver (Figure 1C) 301 
compared with mice fed standard chow.  302 
 303 
TNFSF14 protects against diet-induced obesity, glucose intolerance and insulin resistance. 304 
To further elucidate the functional role of TNFSF14 in obesity and T2D, we compared 305 
TNFSF14 knockout (KO) to wildtype (WT) mice fed either standard chow or HFD. This mouse 306 
model allowed for the effects of endogenous TNFSF14 to be ascertained. There were no 307 
discernible differences in body weight for chow fed mice (Figure 2A). Interestingly, TNFSF14 308 
KO mice were markedly more obese compared with their WT counterparts when placed on 309 
a HFD (Figure 2A). These results were observed in three independent experiments. This 310 
novel data suggests that the presence of TNFSF14 may attenuate diet-induced obesity. In 311 
addition, HFD-fed TNFSF14 KO mice were more glucose intolerant (Figure 2B) and insulin 312 
resistant (Figure 2C) compared with WT controls. Also, HFD-fed TNFSF14 KO mice developed 313 
hyperinsulinemia (Figure 2D). Taken together, these data support the notion that TNFSF14 314 
expression is increased during the metabolic syndrome to work in a compensatory manner 315 
to limit diet-induced obesity and type 2 diabetes.  316 
 317 
TNFSF14 reduces fatty acid induced insulin resistance in L6 myotubes. 318 
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Our in vivo findings provided an insight to explore the direct effect of TNFSF14 on insulin 319 
sensitivity in cells of one of the major metabolic tissue types, skeletal muscle. Impressively, 320 
TNFSF14 treatment promoted insulin sensitivity and overcame palmitate induced insulin 321 
resistance in L6 skeletal muscle cells (Figure 3A).  322 
 323 
TNFSF14 treatment promotes glucose stimulated insulin secretion from pancreatic beta 324 
cells.  325 
Using the pancreatic  cell line MIN6, we demonstrate that glucose stimulated insulin 326 
secretion is significantly elevated in response to TNFSF14 treatment compared with 327 
untreated cells (Figure 3B). Therefore, we show for the first time that insulin secretion may 328 
be directly stimulated in the presence of TNFSF14.   329 
 330 
Endogenous TNFSF14 expression reduces adipocyte hypertrophy and inflammation in 331 
white adipose tissue in HFD-fed obese mice.  332 
We then shifted our focus to investigating the role of TNFSF14 in metabolically relevant 333 
tissues. Firstly, we show that TNFSF14 deficiency promotes adipocyte hypertrophy under 334 
high-fat feeding conditions (Figure 4A, B). Furthermore obesogenic TNFSF14 KO mice had 335 
significantly elevated mRNA levels of the pro-inflammatory cytokine TNF- in their white 336 
adipose tissue compared with WT counterparts (Figure 4C) which indicates that TNFSF14 337 
deficiency is associated with heightened inflammation.  338 
 339 
Hepatic lipid accumulation is promoted in HFD-fed TNFSF14 KO mice.  340 
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We also assessed liver tissue from HFD-fed mice as pathological lipid accumulation is a 341 
hallmark of metabolic disease (Mehlem, et al. 2013). Oil red staining of liver sections 342 
indicated substantial increased lipid accumulation in the livers of TNFSF14 KO mice fed a 343 
HFD compared with WT mice (Figure 5A, B). Histological examination by haematoxylin and 344 
eosin staining further substantiated this. There was also elevated inflammatory cell 345 
infiltration and dilated vasculature in livers of TNFSF14 KO mice (Supplementary Figure 1). 346 
Combined, these data suggest an important role for TNFSF14 in lipid homeostasis. 347 
 348 
Diet-induced obese TNFSF14 KO mice have elevated levels of hepatic lipase. 349 
We hypothesised that there may be an association of TNFSF14 and lipases involved in lipid 350 
homeostasis. When we compared hepatic lipase protein expression in the livers of WT and 351 
TNFSF14 KO mice fed a HFD (Supplementary Figure 2), we unexpectedly observed elevated 352 
hepatic lipase protein expression in livers of TNFSF14 KO mice. We believe that this increase 353 
in hepatic lipase protein is a compensatory response to the high fat diet-induced steatosis.   354 
 355 
Cytokine dysregulation in livers of TNFSF14 KO mice on a HFD. 356 
We aimed to ascertain if TNFSF14 ablation triggers perturbations in cytokine expression in 357 
our diet-induced obese mice by assessing liver expression of cytokines which are known to 358 
be implicated in the pathogenesis of obesity and T2D. Interestingly, there was a trend for 359 
the chemokine CXCL-10 to be increased in livers from HFD-fed TNFSF14 deficient mice 360 
(Supplementary Figure 3A).  361 
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When we explored the effect of TNFSF14 on cytokine protein expression in the livers of 362 
HFD-fed mice, we saw a striking decrease in IL-6 expression in livers from TNFSF14 KO mice 363 
compared with WT counterparts (Figure 6A). In addition, the cytokine IL-10 was drastically 364 
upregulated in the livers of HFD-fed TNFSF14 KO mice compared with WT controls (Figure 365 
6B). Although not significant, there was a trend for IL-1 (Supplementary Figure 3B) and IL-366 
18 (Supplementary Figure 3D) protein expression to be reduced in livers from TNFSF14 KO 367 
livers compared to WT counterparts.  368 
 369 
TNFSF14 deficient mice display dysregulated hepatic mitochondrial respiration when fed a 370 
HFD.  371 
Defects in mitochondrial pathways can trigger metabolic changes such as obesity and insulin 372 
resistance (Baker, et al. 2014). Consequently we measured levels of mitochondrial 373 
respiration in the livers of HFD-fed mice. Levels of respiration using substrates for Complex I 374 
(Figure 7A), Complex II (Figure 7B) and Complex III (Figure 7C) were significantly upregulated 375 
in the livers of obesogenic TNFSF14 KO mice compared with WT mice. Our finding is 376 
consistent with a human study which reported that persons with steatosis have greater 377 
hepatic mitochondrial oxidative metabolism compared with controls (Sunny, et al. 2011). 378 
Hence it is plausible that TNFSF14 deficiency may contribute to hepatic mitochondrial 379 
defects under high fat feeding conditions.  380 
 381 
Ablation of TNFSF14 in hematopoietically derived cells promotes diet-induced obesity and 382 
insulin resistance. 383 
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Given that hematopoietic cells are involved in diet-induced insulin resistance (Solinas, et al. 384 
2007) and are a major source of TNFSF14, we sought to determine whether TNFSF14 385 
deficiency in hematopoietic cells promoted diet-induced obesity and insulin resistance. We 386 
successfully demonstrate that hematopoietic cells are a major source of TNFSF14 that 387 
protects against diet-induced obesity as WT mice reconstituted with TNFSF14 KO bone 388 
marrow displayed significantly elevated diet-induced obesity (Figure 8A) and insulin 389 
resistance (Figure 8B) compared to WT mice reconstituted with WT bone marrow. Therefore 390 

















There is mounting evidence indicating the beneficial effects of the cytokine TNFSF14 in 406 
disease (Dhall et al. 2016; Heo et al. 2016; Krause et al. 2014; Malmestrom et al. 2013; Mana 407 
et al. 2013; Qiao et al. 2017). However the role of TNFSF14 in the development of obesity 408 
and type 2 diabetes remains poorly understood (Bassols et al. 2010a; Dandona et al. 2014). 409 
Our innovative study provides clear evidence that TNFSF14 is elevated in mice as an 410 
adaptive response to attenuate characteristics of the metabolic syndrome. To our 411 
knowledge, we are the first group to examine the functional role of naturally-expressed 412 
endogenous TNFSF14 in a murine model of diet-induced obesity. Mice globally deficient in 413 
TNFSF14 develop obesity, glucose intolerance and impaired insulin sensitivity under high fat 414 
feeding conditions. Excitingly, we also show that lack of TNFSF14 leads to adipocyte 415 
hypertrophy and inflammation, hepatosteatosis and significant defects in hepatic 416 
mitochondrial respiration, indicating that TNFSF14 is required to hinder the development of 417 
complications arising from diet-induced obesity. Moreover, we show through in vitro 418 
experiments that TNFSF14 can overcome palmitate-induced insulin resistance in skeletal 419 
muscle cells and TNFSF14 treatment can directly promote insulin secretion from pancreatic 420 
 cells, signifying that TNFSF14 is metabolically beneficial in promoting insulin signaling and 421 
secretion. The work from our cellular studies is consistent with our finding that HFD-fed WT 422 
mice had improved insulin sensitivity compared with their TNFSF14 KO counterparts. Taken 423 
together, our novel data substantiates our hypothesis that physiological endogenous levels 424 





Cells of the hematopoietic lineage have been shown to play pivotal roles in diabesity 428 
(Solinas et al. 2007). As hematopoietic cells are a major source of TNFSF14, we sought to 429 
determine whether ablation of TNFSF14 in just the hematopoietic cells also promoted diet-430 
induced obesity and insulin resistance. We hypothesized that if hematopoietic TNFSF14 is 431 
the major source of TNFSF14 that protects against diet-induced obesity and insulin 432 
resistance, then WT mice reconstituted with TNFSF14 KO bone marrow will display 433 
pronounced diet-induced obesity and insulin resistance when fed a HFD. If both 434 
hematopoietic and non-hematopoietic sources are involved, then the mice will display an 435 
intermediate phenotype. We conclusively show for the first time that hematopoietic cells 436 
are a source of protective TNFSF14 in our murine model of diet-induced obesity and T2D.  It 437 
would be of interest to further determine the exact type of hematopoietic cell that is 438 
responsible for producing the metabolically beneficial cytokine TNFSF14, which include 439 
specific subsets of T cells, B cells or macrophages. It should be noted that the difference 440 
observed in weight gain and insulin resistance in our bone-marrow reconstitution 441 
experiments were smaller than those observed in our whole-body TNFSF14 knockout 442 
model. This suggests that hematopoietic cells are not the only source of protective TNFSF14 443 
in diet-induced obesity and T2D. This is conceivable as we also demonstrated in our study 444 
that adipose tissue and liver are major sources of TNFSF14. Therefore adipocytes or 445 
hepatocytes may be candidate cells.  446 
 447 
Hepatic lipase, an enzyme involved in lipid metabolism, hydrolyses triglycerides and 448 
phospholipids in lipoproteins and facilitates their metabolism and clearance (Santamarina-449 
Fojo, et al. 2004; Teslovich, et al. 2010). Given the extent of chronic liver damage in 450 
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obesogenic TNFSF14 KO mice, we postulated that TNFSF14 deficiency may be associated 451 
with defects in hepatic lipase activity.  We observed that HFD-fed mice lacking TNFSF14 had 452 
elevated hepatic lipase protein expression compared with their wildtype counterparts. This 453 
surprising result suggests that hepatic lipase may be potentially increased in the absence of 454 
TNFSF14 as an adaptive response to hydrolyse accumulated lipid in the liver (Chen, et al. 455 
2015).   456 
 457 
We next sought to determine whether mitochondrial respiration is influenced by the 458 
TNFSF14 KO phenotype in HFD fed mice. Liver mitochondria control hepatocellular energy 459 
metabolism via ATP synthesis and fatty acid oxidation (Pessayre, et al. 2002). It has 460 
previously been shown that insulin resistance is associated with impaired mitochondrial 461 
function in the liver (Kim, et al. 2008) though the role of mitochondrial function in disease is 462 
complex. In our study, we excitingly show for the first time that obesogenic TNFSF14 463 
deficient mice exhibit a significantly elevated respiration rate when assessing respiration via 464 
Complex I, Complex II and Complex III, which we suggest is a compensatory attempt to 465 
prevent a decrease in ATP synthesis (Gonzalvez, et al. 2013) in the steatotic liver. Therefore, 466 
when mice are metabolically challenged with a HFD, TNFSF14 deficiency may be associated 467 
with dysregulated mitochondrial respiration in the liver. 468 
 469 
The metabolically beneficial role of TNFSF14 in diet-induced obesity may also be associated 470 
with other factors which are potentially a direct result of the upregulation of TNFSF14. 471 
Hence, we conducted cytokine profiling in livers of HFD-fed mice to study the association of 472 
TNFSF14 with other cytokines known to be implicated in the metabolic syndrome. Of 473 
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particular interest are two interleukins, IL-6 and IL-10. Our group previously reported that IL-474 
6 KO mice develop systemic insulin resistance and hepatic inflammation when fed a HFD 475 
(Matthews, et al. 2010). In agreement, HFD-fed IL-6 transgenic mice have lower body and 476 
fat mass, and are more glucose tolerant and insulin sensitive (Sadagurski, et al. 2010), 477 
suggesting that endogenous physiological levels of IL-6 may be beneficial in diet-induced 478 
obesity. Excitingly, we show for the first time that livers from obesogenic TNFSF14 KO mice 479 
have markedly lower hepatic IL-6 expression compared to livers from WT counterparts. The 480 
combined reduction of TNFSF14 and IL-6 expression may be one crucial accelerating factor 481 
implicated in the pathogenesis of obesity-induced liver disease. Indeed, the heightened level 482 
of IL-6 in WT liver supports the notion that IL-6 is metabolically beneficial in limiting HFD-483 
induced steatosis. As some cellular studies have demonstrated that TNFSF14 directly 484 
induces IL-6 (Hosokawa, et al. 2010; Mikami, et al. 2014), it is intriguing to speculate that 485 
TNFSF14 directly regulates IL-6 production in our study. 486 
  487 
We were also interested in the potential association of IL-10 and TNFSF14 as studies have 488 
previously reported that IL-10 is involved in the protection against diet-induced metabolic 489 
dysfunction including hyperinsulinemia (Grant, et al. 2014; Kesherwani, et al. 2015). 490 
Interestingly, mice fed a HFD and lacking TNFSF14 exhibited both hyperinsulinemia and 491 
significantly elevated expression of hepatic IL-10 compared with HFD fed WT mice. We 492 
believe that the increased hepatic IL-10 expression in the TNFSF14 KO mice on a HFD may 493 
be a compensatory mechanism to attempt to reduce hepatic inflammation as evidenced by 494 
the vast infiltration of inflammatory cells in the H&E stained liver sections of the TNFSF14 495 




Our study categorically indicates that endogenous physiological levels of the cytokine 498 
TNFSF14 has a protective role in the pathogenesis of obesity and type 2 diabetes and this 499 
may be facilitated by elevated hepatic IL-6 levels. Other studies have demonstrated that IL-6 500 
behaves as a myokine during exercise to maintain glucose homeostasis (Febbraio, et al. 501 
2004; Pedersen and Fischer 2007; Pedersen, et al. 2004). Indeed, muscle contraction during 502 
exercise appears to increase IL-6 production systemically which stimulates fatty acid 503 
oxidation and inhibits TNF- induced insulin resistance (Pedersen and Fischer 2007). 504 
Therefore, it would be an intriguing future study to examine whether muscle derived IL-6 505 
levels are also reduced in TNFSF14 KO mice fed a high fat diet.  506 
 507 
A major novel aspect of our work is that we are one of the first groups to demonstrate 508 
circulating TNFSF14 levels using an in vivo mouse model. Until now, many studies have only 509 
assessed TNFSF14 levels by flow cytometry or mRNA levels of TNFSF14. Hence measuring 510 
TNFSF14 protein levels, as in our study, is highly relevant. We also feel that our knockout 511 
mouse model possesses a major benefit over studies which utilise transgenic mice. Our 512 
study examines the effects of endogenous TNFSF14 protein which exists at physiological 513 
levels. Unfortunately, studies utilising transgenic mice which overexpress cytokines produce 514 
supra-physiological levels of the protein of interest. For example, in the IL-6 setting, 515 
transgenic IL-6 mice express circulating IL-6 in the 3,000-15,000 pg/mL range (Benedetti, et 516 
al. 1997). Alternatively, endogenous levels of circulating IL-6 in many pathological conditions 517 
in mice only occur between 4-300 pg/mL (Das, et al. 2014; Han, et al. 2017; Wei, et al. 2015; 518 




Our highly innovative study provides persuasive evidence that TNFSF14 expression is 521 
increased during the metabolic syndrome in a compensatory manner to reduce diet-induced 522 
obesity and T2D. Our exciting in vivo findings demonstrate an essential role for TNFSF14 in 523 
limiting high fat diet induced weight gain, glucose intolerance and insulin resistance. 524 
Furthermore, our data suggest a lack of TNFSF14 exacerbates chronic liver injury, 525 
inflammation and results in dysregulation of hepatic mitochondrial respiration. We also 526 
postulate that TNFSF14 may exert its protective effects in the liver via elevated IL-6 levels. 527 
Finally, we have shown for the first time that absence of TNFSF14 in bone marrow cells 528 
promotes obesity and insulin resistance.  In conclusion, our novel data suggest that a 529 
TNFSF14 deficiency exacerbates parameters of the metabolic syndrome under high fat 530 
feeding conditions and provides further evidence to support the development of TNFSF14 531 
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FIGURE LEGENDS 713 
 714 
Figure 1. TNFSF14 levels are increased in high fat fed mice. A high fat diet increases 715 
circulating TNFSF14 protein levels (A) and TNFSF14 mRNA expression in white adipose tissue 716 
(B) and liver (C); n=5-9 mice/group, *p<0.05, mean + SEM. 717 
 718 
Figure 2. TNFSF14 deficiency confers obesity, glucose intolerance, insulin resistance and 719 
hyperinsulinemia on a high fat diet. In a high fat feeding context, endogenous TNFSF14 720 
ablation promotes obesity (A), glucose intolerance (B), insulin resistance (C) and elevated 721 
levels of circulating insulin (D). Glucose and insulin tolerance tests were conducted 12 weeks 722 
after high fat diet commencement; WT: wildtype, KO: TNFSF14 KO; n=14-26 mice/group, 723 
*p<0.05, **p=0.013, mean  SEM. 724 
 725 
Figure 3. TNFSF14 treatment reduces palmitate-induced insulin resistance and promotes 726 
insulin secretion in vitro. Representative immunoblot showing TNFSF14 treatment 727 
promotes insulin sensitivity in L6 skeletal muscle myotubes as indicated by increased 728 
expression of phospho-AKT. -actin served as a housekeeping protein (A). Glucose 729 
stimulated insulin secretion from the MIN6 pancreatic  cell line is elevated after 48hrs of 730 
TNFSF14 treatment (B); n=3 wells/group, p<0.007, mean + SEM. 731 
 732 
Figure 4. TNFSF14 deficiency promotes adipocyte hypertrophy and inflammation in mice 733 
fed a high fat diet. Representative photomicroscopy depicting the reduced degree of 734 
34 
 
adipocyte hypertrophy in the white adipose tissue of WT mice (A) compared to TNFSF14 KO 735 
mice (B) on a high fat diet. Tnf- mRNA expression is significantly increased in white adipose 736 
tissue of high fat fed TNFSF14 KO mice compared with WT counterparts (C); n=6-7 737 
mice/group, *p<0.005, mean + SEM. 738 
 739 
Figure 5. TNFSF14 deficiency promotes liver steatosis in mice fed a high fat diet.  740 
Representative photomicrography showing oil red staining in livers of wildtype (A) and 741 
TNFSF14 KO (B) mice following 12 weeks of high fat feeding. Arrows indicate steatotic 742 
vesicles; n=8 mice/group.  743 
 744 
Figure 6. Effect of TNFSF14 deficiency on cytokine expression in livers from high fat diet 745 
fed mice. TNFSF14 deficiency significantly reduces IL-6 expression (A) and increases IL-10 746 
expression in livers from high fat diet fed mice; n=3-4 mice/group, *p=0.0091, **p=0.03139, 747 
mean + SEM. 748 
 749 
Figure 7. TNFSF14 deficiency promotes mitochondrial compensation in livers of high fat 750 
diet fed mice. Respiration rates in liver mitochondrial homogenates when supplemented 751 
with substrates for either Complex I (A), Complex II (B) or Complex III (C); n=8 mice/group, 752 
*p<0.02, mean + SEM. 753 
 754 
Figure 8. Hematopoietic cells from TNFSF14 KO mice promote high fat diet induced 755 
obesity and insulin resistance. Transfer of bone marrow from TNFSF14 KO mice into WT 756 
35 
 
mice promotes weight gain (A) and insulin resistance (B) in high fat fed mice. Weight 757 
analysis and insulin tolerance testing was conducted 12 weeks after commencement of high 758 
fat feeding; n=10 mice/group, *p<0.05, mean  SEM. 759 
 760 
Supplementary Figure 1. TNFSF14 deficiency promotes hepatic steatosis in high fat diet 761 
fed mice. Representative photomicrographs of hematoxylin and eosin staining of liver 762 
highlighting elevated lipid accumulation in the livers from WT (A) and TNFSF14 KO (B) mice.  763 
 764 
Supplementary Figure 2. TNFSF14 deficiency results in a compensatory increase of hepatic 765 
lipase protein expression in high fat diet fed mice. Western blotting for hepatic lipase in 766 
WT and TNFSF14 KO mice fed a high fat diet (A). -actin served as a housekeeping protein. 767 
Representative photomicrographs of hepatic lipase immunohistochemistry in the livers of 768 
WT (B) and TNFSF14 KO (C) mice fed a high fat diet-fed; 200x magnification; n=4 769 
mice/group. 770 
 771 
Supplementary Figure 3. Effect of TNFSF14 ablation on hepatic cytokine expression from 772 
mice on a high fat diet. CXCL-10 mRNA levels in the livers of WT and TNFSF14 KO mice fed a 773 
high fat diet for 12 weeks (A). There is a trend for lowered IL-1 (B) and IL-18 (C) in livers of 774 
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